Development and Validation of a Nomogram Model for Predicting the Risk of Readmission in Patients with Heart Failure with Reduced Ejection Fraction within 1 Year

Yue Hu, Xiaotong Wang, Shengjue Xiao, Chunyan Huan, Huimin Wu, Tao Xu, Minjia Guo, Hong Zhu, and Defeng Pan

1Department of General Practice, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221004, China
2Department of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221004, China
3Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, 87 Dingjiaqiao, Nanjing, Jiangsu 210009, China

Correspondence should be addressed to Defeng Pan; xzdefengpan@xzhmu.edu.cn

Received 7 May 2022; Accepted 1 September 2022; Published 16 September 2022

Academic Editor: Gaurav Kumar

Copyright © 2022 Yue Hu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The high incidence of readmission for patients with reduced ejection fraction heart failure (HFrEF) can seriously affect the prognosis. In this study, we aimed to build a simple predictive model to predict the risk of heart failure (HF) readmission in patients with HFrEF within one year of discharge from the hospital. This retrospective study enrolled patients with HFrEF evaluated in the Heart Failure Center of the Affiliated Hospital of Xuzhou Medical University from January 2018 to December 2020. The patients were allocated into the readmission or nonreadmission group, according to whether HF readmission occurred within 1 year of hospital discharge. Subsequently, all patients were randomly divided into training and validation sets in a 7:3 ratio. A nomogram was established according to the results of univariate and multivariate logistic regression analysis. Finally, the area under the receiver operating characteristic curve (AUC-ROC), calibration plot, and decision curve analysis (DCA) were used to validate the nomogram. Independent risk factors for HF readmission of patients with HFrEF within 1 year of hospital discharge were as follows: age, body mass index, systolic blood pressure, diabetes mellitus, left ventricular ejection fraction, and angiotensin receptor-neprilysin inhibitors. The AUC-ROC of the training and validation sets were 0.833 (95% confidence interval (CI): 0.793-0.866) and 0.794 (95% CI: 0.727-0.852), respectively, which have an excellent distinguishing ability. The predicted and observed values of the calibration curve also showed good consistency. DCA also confirmed that the nomogram had good clinical value. In conclusion, we constructed an accurate and straightforward nomogram model for predicting the 1-year HF readmission risk in patients with HFrEF. This nomogram can guide early clinical intervention and improve patient prognosis.

1. Introduction

Heart failure (HF) is the ultimate outcome of various heart diseases, which seriously affect people’s quality of life [1]. According to epidemiologic studies, HF has become an epidemic disease, with more than 38 million patients with HF worldwide [2]. With the aging of the population, the prevalence of HF increases, exceeding 10% in people over 70 years of age [3, 4]. HF has high mortality and low survival rates comparable to malignant tumors, and the 5-year survival rates for men and women with HF were 25% and 38%, respectively [5].

The 2021 European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and chronic HF classified HF based on the left ventricular ejection fraction (LVEF) as follows: heart failure with reduced ejection fraction (HFrEF) (LVEF ≤ 40%), heart failure with mildly reduced ejection fraction (HFrEF) (LVEF = 41–49%), and
heart failure with preserved ejection fraction (HFpEF) (LVEF ≥ 50%) [6]. HFrEF, also known as systolic HF, accounts for about 50% of patients with HF [7]. A study has shown that compared with HFmrEF and HFpEF, HFrEF has a higher mortality rate and worse prognosis [8]. HF is the main reason for admission and readmission in patients over 65 years old, and the readmission rate within one year for HF exacerbations is as high as 35% [9–11]. Studies have shown that the decline in physical status in patients with HF is closely related to repeated readmissions and not only leads to the decline of cardiac function but also affects the patient’s treatment compliance, which creates an enormous economic burden for patients and the healthcare system [12]. Therefore, accurate recognition of patients’ risk of readmission within 1 year and early intervention is critical to patient outcomes.

A nomogram is a visualized model which can transform complex regression equations into visual graphs, and it is widely used for disease diagnosis and prognosis [13]. In predicting readmission or survival rate in patients with HF, studies have shown that the nomogram is an ideal model that can reduce readmission and mortality [14, 15]. However, there have been no studies of HF readmission in patients with HFrEF. Therefore, we wanted to construct a nomogram to predict the 1-year risk of HF readmission in HFrEF, which could guide clinical diagnosis, advance intervention, and improve patients’ quality of life.

2. Methods

2.1. Study Population and Design. This retrospective study was based on the database of the Heart Failure Center, The Affiliated Hospital of Xuzhou Medical University. Patients diagnosed with HFrEF according to the 2016 ESC Guidelines from January 2018 to December 2020 were enrolled [16]. This study was conducted according to the principles of the Declaration of Helsinki and approved by the Medical Research Ethics Committee of the Affiliated Hospital of Xuzhou Medical University (approval number XYFY2022-KL094-01). Because the study was a single-center retrospective study, the review committee waived the requirement for written informed consent.

The inclusion criteria were as follows: (1) HFrEF diagnosed according to the 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic HF [16] and (2) New York Heart Association (NYHA) classification of cardiac function levels II to IV. The exclusion criteria were as follows: (1) patients lost to follow-up for various reasons, (2) patients with missing critical clinical data, (3) a history of malignant tumor, (4) patients with severe end-stage disease of essential organs such as the liver, kidney, or brain, and (5) other reasons. The Heart Failure Center has established a follow-up system for all patients, and all follow-up data can be accessed. The study’s endpoint was defined as HF readmission within 1 year of hospital discharge.

2.2. Predictor Variables. Through a review of the literature, we collected various factors that may influence patient prognosis, including demographic data, comorbidities, hematologic indicators, echocardiographic indicators, medication at admission, and device therapy. As shown in Table 1, a total of 43 parameters were obtained at admission. All indicators were obtained within 24 hours of admission.

2.3. Statistical Analysis. In this study, R version 3.6.4, Stata version 13.0, and SPSS version 22.0 were used for statistical analysis. The measurement data conforming to the normal distribution were expressed as mean ± standard deviation (X ± S), and the independent sample t-test was used for intergroup comparison. Non-normally distributed data were represented by the median (M) and interquartile ranges (M (P25, P75)), and nonparametric tests were used for intergroup comparison. For the assessment of normality, we used the Shapiro-Wilk test. The counting data were expressed as frequency and percentage (%), and the chi-square test was used for intergroup comparison. P < 0.05 indicates statistical significance. A nomogram was established according to the results of univariate and multivariate logistic regression analysis. The area under the receiver-operating characteristic (AUC-ROC) curve was used to verify the discrimination of the nomogram, and a bootstrap self-sampling method (B = 1000) was used to internally validate the model and plot calibration curves. Finally, decision curve analysis (DCA) was used to confirm the clinical benefit of this nomogram.

3. Results

3.1. Baseline Characteristics. From January 2018 to December 2020, there were 910 patients with HFrEF in the Heart Failure Center of Affiliated Hospital of Xuzhou Medical University. Based on the inclusion and exclusion criteria, 700 patients were eventually enrolled. The patients were divided into readmission and nonreadmission groups according to whether they were readmitted for HF within 1 year. Moreover, we randomly divided all patients into training (n = 490) and validation (n = 210) sets in a ratio of 7:3. The patient selection process is shown in Figure 1.

The baseline data of these patients are shown in Table 1. A total of 217 patients were readmitted, with an end-point event rate of 31%. The mean age of the patients in the readmission group was 65.0 ± 12.7, of whom 153 (70.5%) were male, compared with 60.0 ± 15.2 and 321 (66.5%) in the nonreadmission group. The variables that showed significant differences between the readmission and nonreadmission groups were as follows: age, NYHA class, body mass index (BMI), systolic blood pressure (SBP), diabetes mellitus (DM), coronary heart disease, anemia, estimated glomerular filtration rate (eGFR), uric acid, NT-proBNP, LVEF, and angiotensin receptor-neprilysin inhibitors (ARNI) (all P < 0.05).

3.2. Univariate and Multivariate Logistic Analysis of HF Readmission within 1 Year. We included the variables from univariate logistic analysis with P < 0.05 in subsequent multivariate logistic analysis (Table 2). Univariate logistic analysis showed that factors associated with HF readmission within 1 year in patients with HFrEF included the following: age, NYHA class, BMI, SBP, DM, coronary heart disease, anemia, eGFR, uric acid, LVEF, and ARNI (all P < 0.05). We included these 11 variables into the multivariate logistic analysis, and
Table 1: Baseline characteristics of the nonreadmission group and readmission group.

| Variables                      | Nonreadmission group (n = 483) | Readmission group (n = 217) | P value |
|--------------------------------|---------------------------------|----------------------------|---------|
| Age (years)                    | 59.95 ± 15.222                  | 64.98 ± 12.646              | <0.001  |
| Gender (n, %)                  |                                 |                            | 0.290   |
| Male                           | 321 (66.5%)                     | 153 (70.5%)                |         |
| Female                         | 162 (33.5%)                     | 64 (29.5%)                 |         |
| NYHA class, (n, %)             |                                 |                            | 0.045   |
| II                             | 81 (16.8%)                      | 22 (10.1%)                 |         |
| III                            | 321 (66.5%)                     | 149 (68.7%)                |         |
| IV                             | 81 (16.8%)                      | 46 (21.2%)                 |         |
| BMI (kg/m²)                    | 21.26 (20.14,22.48)             | 21.03 (20.10,21.77)        | <0.001  |
| SBP (mmHg)                     |                                 |                            | <0.001  |
| <120                           | 104 (21.5%)                     | 91 (41.9%)                 |         |
| >140                           | 99 (20.5%)                      | 57 (26.3%)                 |         |
| 120–140                        | 280 (58.0%)                     | 69 (31.8%)                 |         |
| DBP (mmHg)                     | 75 (66.85)                      | 72 (62.5,86)               | 0.059   |
| >60                            | 327 (67.7%)                     | 131 (60.4%)                |         |
| ≤60                            | 156 (32.3)                      | 86 (39.6)                  |         |
| Heart rate (b.p.m.)            | 74 (63.88)                      | 72 (59.89)                 | 0.196   |
| Smoking (n, %)                 |                                 |                            | 0.115   |
| No                             | 332 (68.7%)                     | 136 (62.7%)                |         |
| Yes                            | 151 (31.3%)                     | 81 (37.3%)                 |         |
| Drinking (n, %)                |                                 |                            | 0.468   |
| No                             | 300 (62.1%)                     | 141 (65%)                  |         |
| Yes                            | 183 (37.9%)                     | 76 (35%)                   |         |
| Comorbidities, (n, %)          |                                 |                            |         |
| Hypertension                   | 180 (37.3%)                     | 92 (42.4%)                 | 0.198   |
| Diabetes                       | 94 (19.5%)                      | 91 (41.9%)                 | <0.001  |
| Atrial fibrillation            | 60 (12.4%)                      | 39 (18%)                   | 0.051   |
| Stroke                         | 54 (11.2%)                      | 35 (16.1%)                 | 0.069   |
| Coronary heart disease         | 158 (32.7%)                     | 89 (41%)                   | 0.034   |
| Dyslipidemia                   | 59 (12.2%)                      | 24 (11.1%)                 | 0.662   |
| Myocardial infarction          | 79 (16.4%)                      | 45 (20.7%)                 | 0.16    |
| COPD                           | 21 (4.3%)                       | 12 (5.5%)                  | 0.495   |
| Chronic kidney disease         | 15 (3.1%)                       | 9 (4.1%)                   | 0.484   |
| Anemia                         | 150 (31.1%)                     | 84 (38.7%)                 | 0.047   |
| Fasting glucose (mmol/L)       | 7 (5.45,10.35)                  | 7.11 (5.425,10.33)         | 0.846   |
| Serum creatinine (μmol/L)      | 91 (67,137)                     | 90 (71,123)                | 0.566   |
| eGFR (mL/min)                  | 74.37 (45.24,95.32)             | 67.84 (47.4,86.79)         | 0.024   |
| Hemoglobin (g/L)               | 130 (109,147)                   | 132 (116,150)              | 0.057   |
| Serum sodium (mmol/L)          | 139.37 (135.88,142.4)           | 140 (137.36,142.28)        | 0.145   |
| Serum kalium (mmol/L)          | 4.05 (3.67,4.46)                | 4.1 (3.69,4.515)           | 0.199   |
| Total cholesterol (mmol/L)     | 4.19 (3.34,5.52)                | 4.24 (3.415,5.12)          | 0.311   |
| LDL-C (mmol/L)                 | 2.56 (1.79,3.49)                | 2.57 (1.955,3.235)         | 0.859   |
| Uric acid (μmol/L)             | 409 (336,537)                   | 438 (342.5,577.5)          | 0.048   |
| NT-proBNP (pg/mL)              | 2338 (1020,5675)                | 3510 (1452,5868)           | 0.044   |
| LVEF (%)                       | 31 (28.35)                      | 29 (25.5,33)               | <0.001  |
| LVEDd (mm)                     | 72 (65,78)                      | 73 (62,85)                 | 0.134   |
| Medication at admission (n, %) |                                 |                            |         |
| ACEI                           | 71 (14.7%)                      | 36 (16.6%)                 | 0.52    |
Table 1: Continued.

| Variables                              | Nonreadmission group (n = 483) | Readmission group (n = 217) | P value |
|----------------------------------------|-------------------------------|-----------------------------|---------|
| ARB                                    | 110 (22.8%)                   | 36 (16.6%)                  | 0.063   |
| ARNI                                   | 329 (68.1%)                   | 83 (38.2%)                  | <0.001  |
| Beta-blockers                          | 408 (84.5%)                   | 187 (86.2%)                 | 0.559   |
| Aldosterone receptor antagonist        | 434 (89.9%)                   | 195 (89.9%)                 | 0.998   |
| Ivabradine                             | 1 (0.2%)                      | 2 (0.9%)                    | 0.181   |
| Diuretic                               | 440 (91.1%)                   | 200 (92.2%)                 | 0.64    |
| Digitalis                              | 186 (38.5%)                   | 91 (41.9%)                  | 0.391   |
| Device therapy (n, %)                  |                               |                             |         |
| CRT-D                                  | 2 (0.4%)                      | 3 (1.4%)                    | 0.159   |
| CRT-P                                  | 2 (0.4%)                      | 2 (0.9%)                    | 0.41    |
| Pacemaker                              | 11 (2.3%)                     | 10 (4.6%)                   | 0.095   |
| ICD                                    | 2 (0.4%)                      | 0 (0%)                      | 0.342   |

BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; COPD: chronic obstructive pulmonary disease; eGFR: estimated glomerular filtration rate; LDL-C: low-density lipoprotein cholesterol; NT-proBNP: N-terminal-pro brain natriuretic peptide; LVEF: left ventricular ejection fraction; LVEDd: left ventricular end-diastolic diameter; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blockers; ARNI: angiotensin receptor neprilysin inhibitors; CRT-D: CRT defibrillator; CRT-P: CRT pacemaker; ICD: implantable cardioverter defibrillator.

From January 2018 to December 2020, HFrEF patients were selected from the heart failure center of the affiliated hospital of Xuzhou medical university (n = 910). 700 patients were included. The groups were randomly divided in a 7:3 ratio: Training set (n = 490) and Validation set (n = 210). Nomogram development and Nomogram validation.

210 patients were excluded:
1. Patients who are lost to follow-up (n = 87)
2. Patients with missing important clinical data (n = 56)
3. A history of malignant tumor (n = 16)
4. Patients with severe end-stage disease of essential organs such as liver, kidney or brain (n = 45)
5. Other reasons (n = 6)

3.3. Clinical Features of the Training and Validation Sets. To prevent overfitting of the clinical predictive model in the analysis of influencing factors, patients with HFrEF were randomly divided into training and validation sets in a ratio of 7:3. As shown in Table 3, the training and validation sets were not statistically different in clinical characteristics. This shows that our dataset division is reasonable and comparable.

3.4. Development and Validation of the Nomogram. Based on the relative weights of the risk factors in Table 2, a nomogram was drawn as shown in Figure 2. For the validation of the nomogram, ROC curves were first drawn for the
training and validation set data. The AUC-ROC for the training set was 0.833 (95% CI: 0.793-0.866), and AUC-ROC for the validation set was 0.794 (95% CI: 0.727-0.852). This suggests that the model’s discriminative ability was good, as shown in Figure 3. Then, we used the bootstrap self-sampling method to repeat this 1000 times and drew the calibration curves of this nomogram for the training and verification sets. The results showed that the predicted probability of this model is in good agreement with the actual probability and the model calibration is good, as shown in Figure 4. At last, to verify the clinical benefit of the model, DCA curves were drawn for the training and validation set data. According to the DCA curves, the net benefit of the training and verification sets was significantly higher than the two extremes, as shown in Figure 5. Therefore, the nomogram has good clinical benefits.

### 4. Discussion

Studies have shown that patients with HFrEF have a 25.3–35.4% chance of being readmitted to the hospital for HF within 1 year, which is consistent with our study’s finding of the 31% HF readmission rate. The high prevalence and mortality of HF have placed a heavy burden on healthcare systems, and the global prevalence of HF is projected to reach 25% by 2030; HFrEF is the type of HF with the worst prognosis [17]. Although medical advances in treating HF have progressed, its prevalence and readmission rates are still increasing [18]. Therefore, early identification of readmission risks for patients with HF and implementation of early intervention is of great significance for patient prognosis [19]. In our study, we found that age, BMI, SBP, diabetes, LVEF, and ARNI were an independent risk factor for HF readmission within 1 year in patients with HFrEF.

The incidence of HF increases with age and is accompanied by changes in the heart structure and function [3, 4, 20, 21]. Ferreira et al. showed that elderly patients with HFrEF had a poor prognosis, and cardiovascular markers positively correlated with age were related to extracellular matrix organization and inflammatory processes [22]. For cardiovascular disease, age is not only a significant risk factor but can even determine the prognosis of HF [23, 24]. Economic development has improved peoples’ living standards, and obesity has become a public health concern [25]. A study has shown that a lower BMI is strongly related to an increased risk of all-cause death from cardiovascular disease [26] and low BMI has also been identified as an independent risk factor for all-cause readmission [14].

Hypertension is the most common and important risk factor for HF, and 75% of patients with HF have hypertension, and studies have shown that long-term stable blood pressure control can reduce HF risk by 50% [27, 28]. Studies have shown that both high and low systolic blood pressure will lead to a poor prognosis for patients with HFrEF, which is consistent with our findings [29–31]. DM is common, accounting for about 40% of HF patients and also adversely affects the prognosis of patients with HF [32, 33]. The study by Mac Donald et al. showed that DM was a significant independent predictor of high mortality and HF readmission [34]. The mechanism of how hyperglycemia affects the

---

**Table 2: Univariate and multivariate logistic analysis for the readmission within 1 year.**

| Variables                  | Univariate analysis OR (95% CI) | P value | Multivariate analysis OR (95% CI) | P value |
|----------------------------|---------------------------------|---------|----------------------------------|---------|
| Age (years)                | 1.025 (1.013,1.037)             | <0.001  | 1.033 (1.018,1.049)              | <0.001  |
| NYHA class (n, %)          |                                 |         |                                  |         |
| II                         | 1.000                           |         | 1.000                            |         |
| III                        | 1.709 (1.027,2.845)             | <0.001  | 1.355 (0.756,2.427)              | <0.001  |
| IV                         | 2.091 (1.154,3.788)             | <0.001  | 1.646 (0.824,3.287)              | <0.001  |
| BMI (kg/m²)                | 0.787 (0.715,0.867)             | <0.001  | 0.783 (0.699,0.876)              | <0.001  |
| SBP (mmHg)                 |                                 |         |                                  |         |
| <120                       | 1.000                           |         | 1.000                            |         |
| >140                       | 0.615 (0.402,0.942)             | <0.001  | 0.716 (0.430,1.194)              | <0.001  |
| 120–140                    | 0.225 (0.152,0.333)             | <0.001  | 0.197 (0.194,0.479)              |         |
| Comorbidities (n, %)       |                                 |         |                                  |         |
| Diabetes                   | 2.989 (2.103,4.247)             | <0.001  | 3.302 (2.182,4.996)              | <0.001  |
| Coronary heart disease     | 1.430 (1.028,1.991)             | 0.034   | 1.278 (0.856,1.908)              | 0.230   |
| Anemia                     | 1.402 (1.004,1.959)             | 0.048   | 1.487 (0.994,2.223)              | 0.053   |
| eGFR (mL/min)              | 0.994 (0.988,0.999)             | 0.029   | 1.001 (0.993,1.008)              | 0.810   |
| Uric acid (μmol/L)         | 1.001 (1.000,1.002)             | 0.033   | 1.001 (1.000,1.002)              | 0.093   |
| NT-BNP (pg/mL)             | 1.000 (1.000,1.000)             | 0.181   |                                  |         |
| LVEF (%)                   | 0.925 (0.896,0.955)             | <0.001  | 0.901 (0.867,0.937)              | <0.001  |
| Medication at admission (n, %) | 0.290 (0.208,0.405) | <0.001  | 0.254 (0.172,0.375) | <0.001  |

BMI: body mass index; SBP: systolic blood pressure; eGFR: estimated glomerular filtration rate; NT-proBNP: N-terminal-pro brain natriuretic peptide; LVEF: left ventricular ejection fraction; ARNI: angiotensin receptor neprilysin inhibitors.
Table 3: Baseline characteristics of validation training sets.

| Variables                        | Validation set (n = 210) | Training set (n = 490) | P value |
|----------------------------------|--------------------------|------------------------|---------|
| Age (years)                      | 60.39 ± 15.774           | 61.99 ± 14.13          | 0.185   |
| Gender (n, %)                    |                          |                        | 0.832   |
|     Male                         | 141 (67.1%)              | 333 (68%)              |         |
|     Female                       | 69 (32.9%)               | 157 (32%)              |         |
| NYHA class (n, %)               |                          |                        | 0.86    |
|     II                           | 29 (13.8%)               | 74 (15.1%)             |         |
|     III                          | 141 (67.1%)              | 329 (67.1%)            |         |
|     IV                           | 40 (19%)                 | 87 (17.8%)             |         |
| BMI (kg/m²)                      | 21.26 (20.14, 22.48)     | 21.03 (20.10, 21.77)   | 0.449   |
| SBP (mmHg)                       |                          |                        | 0.053   |
|     <120                         | 53 (25.2%)               | 142 (29.0%)            |         |
|     >140                         | 38 (18.1%)               | 118 (24.1%)            |         |
|     120–140                      | 119 (56.7%)              | 230 (46.9%)            |         |
| DBP (mmHg)                       |                          |                        | 0.652   |
|     >60                          | 140 (66.7%)              | 318 (64.9%)            |         |
|     ≤60                          | 70 (33.3%)               | 172 (35.1%)            |         |
| Heart rate (b.p.m.)              | 73 (62.88.25)            | 74 (62.88.25)          | 0.947   |
| Smoking (n, %)                   |                          |                        | 0.063   |
|     No                           | 151 (71.9%)              | 317 (64.7%)            |         |
|     Yes                          | 59 (28.1%)               | 173 (35.3%)            |         |
| Drinking (n, %)                  |                          |                        | 0.252   |
|     No                           | 139 (66.2%)              | 302 (61.6%)            |         |
|     Yes                          | 71 (33.8%)               | 188 (38.4%)            |         |
| Comorbidities (n, %)             |                          |                        |         |
|     Hypertension                 | 70 (33.3%)               | 202 (41.2%)            | 0.050   |
|     Diabetes                     | 56 (26.7%)               | 129 (26.3%)            | 0.925   |
|     Atrial fibrillation          | 27 (12.9%)               | 72 (14.7%)             | 0.523   |
|     Stroke                       | 34 (16.2%)               | 55 (11.2%)             | 0.071   |
|     Coronary heart disease       | 76 (36.2%)               | 171 (34.9%)            | 0.743   |
|     Dyslipidemia                 | 27 (12.9%)               | 56 (11.4%)             | 0.592   |
|     Myocardial infarction        | 37 (17.6%)               | 87 (17.8%)             | 0.966   |
|     COPD                         | 10 (4.8%)                | 23 (4.7%)              | 0.969   |
|     Chronic kidney disease       | 5 (2.4%)                 | 19 (3.9%)              | 0.319   |
|     Anemia                       | 65 (31.0%)               | 169 (34.5%)            | 0.363   |
| Fasting glucose (mmol/L)         | 7.17 (5.3825, 10.3275)   | 7.04 (5.445, 10.345)   | 0.78    |
| Serum creatinine (μmol/L)        | 92.5 (67.75, 132)        | 89 (68, 131)           | 0.597   |
| eGFR (mL/min)                    | 69.925 (44.2225, 92.4325)| 72.89 (47.2, 92.92)    | 0.767   |
| Hemoglobin (g/L)                 | 130 (109, 147)           | 132 (116, 150)         | 0.906   |
| Serum sodium (mmol/L)            | 140 (136, 143)           | 140 (136.6, 142.1)     | 0.841   |
| Serum kalium (mmol/L)            | 4.04 (3.69, 4.4325)      | 4.075 (3.67, 4.48)     | 0.528   |
| Total cholesterol (mmol/L)       | 4.28 (3.365, 5.3425)     | 4.2 (3.355, 5.315)     | 0.79    |
| LDL-C (mmol/L)                   | 2.61 (1.8075, 3.45)      | 2.535 (1.825, 3.3525)  | 0.612   |
| Uric acid (μmol/L)               | 429.5 (346.75, 576.25)   | 413 (332.75, 538)      | 0.084   |
| NT-proBNP (pg/mL)                | 2433 (953.25, 6142.25)   | 2799 (1180.5, 5731.25) | 0.524   |
| LVEF (%)                         | 31 (27.34)               | 31 (27.34)             | 0.893   |
| LVEDD (mm)                       | 73 (63.75, 80)           | 71 (64.79)             | 0.628   |
| Medication at admission (n, %)   |                          |                        |         |
|     ACEI                          | 28 (13.3%)               | 79 (16.1%)             | 0.168   |
The prognosis of patients with HF has not been fully elucidated; it is speculated to be related to the following factors [35–37]: (1) directly or indirectly affecting myocardial cell function through vascular injury, (2) persistent hyperglycemia-induced oxidative stress leading to cardiomyocyte failure and necrosis, (3) irreversible advanced glycosylation end-products (AGEs), which reduce myocardial contractility and compliance, and (4) diabetic nephropathy may limit the use or uptitration of renin–angiotensin–aldosterone system (RAAS) blockade agents [38].

LVEF is a parameter commonly used to evaluate left ventricular systolic function, which can reliably measure left ventricular ejection fraction. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; COPD: chronic obstructive pulmonary disease; eGFR: estimated glomerular filtration rate; LDL-C: low-density lipoprotein cholesterol; NT-proBNP: N-terminal pro-brain natriuretic peptide; LVEF: left ventricular ejection fraction; LVEDd: left ventricular end-diastolic diameter; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blockers; ARNI: angiotensin receptor neprilysin inhibitors; CRT-D: CRT defibrillator; CRT-P: CRT pacemaker; ICD: implantable cardioverter defibrillator.

Figure 2: Nomogram used for predicting the risk of readmission in patients with HFrEF within 1 year. BMI: body mass index; SBP: systolic blood pressure; LVEF: left ventricular ejection fraction; ARNI: angiotensin receptor neprilysin inhibitor.
ventricular function and structure [39]. Studies have shown that LVEF is closely related to the prognosis of patients with HFrEF, and the recovery of ejection fractions can reduce patients’ readmission rate and mortality [40, 41], which is consistent with our study. Sacubitril-valsartan is the first dual inhibitor of a novel anti-HF drug called ARNI for treating patients with HFrEF [16]. In this study, ARNI was a protective factor for readmission in patients with HFrEF. Studies have shown that ARNI has not only good efficacy in reversing left ventricular remodeling and reducing hospitalizations associated with HF but also a positive effect on reversing left atrial remodeling [42, 43]. The 2021 ESC Guidelines state that ARNI could further reduce the risk of HF readmission in patients with HFrEF by 21% and the risk of all-cause death by 16% [44].

Our study has some limitations. First, the retrospective cohort design limited this study because of missing important data (8%), participants who were lost to follow up (12%), and missing data on some interesting variables, such as iron status and cystatin-C. In addition, data on ARNI or other medication usage may be underestimated, as these medications may have been initiated after the first HF admission. Those medication changes after discharge and before readmission were not counted because medication...
use was defined as the medications listed during the first HF admission. Second, this was a single-center study, which lacks external validation.

5. Conclusion

We constructed an accurate and simple nomogram for predicting the risk of HF readmission within 1 year in patients with HFrEF. The nomogram can guide early clinical intervention and improve patient prognosis and quality of life. To ensure generality, this model requires external validation.

Data Availability

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

Yue Hu developed the analysis plan and the writing of the paper. Shengjue Xiao and Xiaotong Wang undertook the data analysis. Chunyan Huan, Huimin Wu, Tao Xu, and Minjia Guo collected the dataset and provided advice on its analysis. Defeng Pan guided the analysis and made substantial improvements to the paper. Hong Zhu supervised the study and contributed to the data analysis plan. Yue Hu, Xiaotong Wang, and Shengjue Xiao contributed equally to this work.

Acknowledgments

This work was supported by grants from the Applied Basic Research Project of Xuzhou to Defeng Pan (grant number: KC20097).

References

[1] M. Taneike, M. Nishida, K. Nakanishi et al., “Alpha-Klotho is a novel predictor of treatment responsiveness in patients with heart failure,” Scientific Reports, vol. 11, no. 1, p. 2058, 2021.
[2] E. Braunwald, “The war against heart failure: The Lancet lecture,” Lancet, vol. 385, no. 9970, pp. 812–824, 2015.
[3] A. Mosterd and A. W. Hoes, “Clinical epidemiology of heart failure,” Heart, vol. 93, no. 9, pp. 1137–1146, 2007.
[4] A. Dhingra, A. Garg, S. Kaur et al., “Epidemiology of heart failure with preserved ejection fraction,” Current Heart Failure Reports, vol. 11, no. 4, pp. 354–365, 2014.
[5] F. P. Brouwers, R. A. de Boer, P. van der Harst et al., “Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND,” European Heart Journal, vol. 34, no. 19, pp. 1424–1431, 2013.
[6] T. A. McDonagh, M. Metra, M. Adamo et al., “2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC,” Revista Española de Cardiología (English Edition), vol. 75, no. 6, p. 523, 2022.
[7] K. S. Shah, H. Xu, R. A. Matsouaka et al., “Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes,” Journal of the American College of Cardiology, vol. 70, no. 20, pp. 2476–2486, 2017.
[8] V. Bhambhani, J. R. Kizer, J. A. C. Lima et al., “Predictors and outcomes of heart failure with mid-range ejection fraction,” European Journal of Heart Failure, vol. 20, no. 4, pp. 651–659, 2018.

[9] D. Mozaffarian, E. J. Benjamin, A. S. Go et al., “Heart disease and stroke statistics–2015 update: a report from the American Heart Association,” Circulation, vol. 131, no. 4, pp. e229–322, 2015.

[10] E. A. Bocchi, “Heart failure in South America,” Current Cardiology Reviews, vol. 9, no. 2, pp. 147–156, 2013.

[11] M. Tsuchihashi-Makaya, S. Hamaguchi, S. Kinugawa et al., “Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction a report from the Japanese cardiac registry of heart failure in cardiology (JCARE-CARD),” Circulation Journal, vol. 73, no. 10, pp. 1893–1900, 2009.

[12] M. Gheorghiade, F. Follath, P. Ponikowski et al., “Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of cardiology and endorsed by the European Society of Intensive Care Medicine,” European Journal of Heart Failure, vol. 12, no. 5, pp. 423–433, 2010.

[13] V. P. Balachandran, M. Gonen, J. J. Smith, and R. P. DeMatteo, “Nomograms in oncology: more than meets the eye,” The Lancet Oncology, vol. 16, no. 4, pp. e173–e180, 2015.

[14] M. Yang, L. Tao, H. An et al., “A novel nomogram to predict all-cause readmission or death risk in Chinese elderly patients with heart failure,” ESC Heart Failure, vol. 7, no. 3, pp. 1015–1024, 2020.

[15] S. Barlera, L. Tavazzi, M. G. Franzosi et al., “Predictors of mortality in 6975 patients with chronic heart failure in the Gruppo Italiano per lo studio della Streptochinasi nell’Infarto miocardico-heart failure trial,” Circulation: Heart Failure, vol. 9, no. 1, pp. 1–10, 2016.

[16] F. Dellaﬁore, C. Arrigoni, F. Pittella, G. Conte, A. Magon, and R. Caruso, “Paradox of self-care gender differences among Italian patients with chronic heart failure: ﬁndings from a real-world cross-sectional study,” BMJ Open, vol. 8, no. 9, article e021966, 2018.

[17] M. Adib-Hajbaghery, F. Maghminejad, and A. Abbasi, “The role of continuous care in reducing readmission for patients with heart failure,” Journal of Caring Sciences, vol. 2, no. 4, pp. 255–267, 2013.

[18] J. D. Davis, M. A. Olsen, K. Bonmarito et al., “All-Payer Analysis of Heart Failure Hospitalization 30-Day Readmission: Comorbidities Matter,” The American Journal of Medicine, vol. 130, no. 1, pp. 93.e9–93.e28, 2017.

[19] K. A. Ammar, S. J. Jacobsen, D. W. Mahoney et al., “Prevalence and prognostic signiﬁcance of heart failure stages,” Circulation, vol. 115, no. 12, pp. 1563–1570, 2007.

[20] R. Kerzner, B. F. Gage, K. E. Freedland, and M. W. Rich, “Predictors of mortality in younger and older patients with heart failure and preserved or reduced left ventricular ejection fraction,” American Heart Journal, vol. 146, no. 2, pp. 286–290, 2003.

[21] J. P. Ferreira, W. Ouwerkerk, B. T. Santema et al., “Differences in biomarkers and molecular pathways according to age for patients with HFrEF,” Cardiovascular Research, vol. 117, no. 10, pp. 2228–2236, 2021.

[22] M. Doshi, E. Streja, C. M. Rhee et al., “Examining the robustness of the obesity paradox in maintenance hemodialysis patients: a marginal structural model analysis,” Nephrology Dialysis Transplantation, vol. 31, no. 8, pp. 1310–1319, 2016.

[23] A. Dattagupta and S. Immaneni, “ST2: current status,” Indian Heart Journal, vol. 70, Suppl 1, pp. S96–S101, 2018.

[24] D. Moza, V. Bhambhani, J. R. Kizer, J. A. C. Lima et al., “Prevalence of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension,” JAMA, vol. 278, no. 3, pp. 212–216, 1997.

[25] D. Moza, V. Bhambhani, J. R. Kizer, J. A. C. Lima et al., “Prevalence of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension,” JAMA, vol. 278, no. 3, pp. 212–216, 1997.

[26] M. Gheorghiade, F. Follath, P. Ponikowski et al., “Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of cardiology and endorsed by the European Society of Intensive Care Medicine,” European Journal of Heart Failure, vol. 12, no. 5, pp. 423–433, 2010.

[27] M. Yang, L. Tao, H. An et al., “A novel nomogram to predict all-cause readmission or death risk in Chinese elderly patients with heart failure,” ESC Heart Failure, vol. 7, no. 3, pp. 1015–1024, 2020.

[28] S. Barlera, L. Tavazzi, M. G. Franzosi et al., “Predictors of mortality in 6975 patients with chronic heart failure in the Gruppo Italiano per lo studio della Streptochinasi nell’Infarto miocardico-heart failure trial,” Circulation: Heart Failure, vol. 6, no. 1, pp. 31–39, 2013.

[29] M. Ponikowski, A. A. Voors, S. D. Anker et al., “2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure,” European Journal of Heart Failure, vol. 18, no. 8, pp. 891–975, 2016.

[30] F. Dellaﬁore, C. Arrigoni, F. Pittella, G. Conte, A. Magon, and R. Caruso, “Paradox of self-care gender differences among Italian patients with chronic heart failure: ﬁndings from a real-world cross-sectional study,” BMJ Open, vol. 8, no. 9, article e021966, 2018.

[31] M. Adib-Hajbaghery, F. Maghminejad, and A. Abbasi, “The role of continuous care in reducing readmission for patients with heart failure,” Journal of Caring Sciences, vol. 2, no. 4, pp. 255–267, 2013.

[32] J. D. Davis, M. A. Olsen, K. Bonmarito et al., “All-Payer Analysis of Heart Failure Hospitalization 30-Day Readmission: Comorbidities Matter,” The American Journal of Medicine, vol. 130, no. 1, pp. 93.e9–93.e28, 2017.

[33] K. A. Ammar, S. J. Jacobsen, D. W. Mahoney et al., “Prevalence and prognostic signiﬁcance of heart failure stages,” Circulation, vol. 115, no. 12, pp. 1563–1570, 2007.

[34] R. Kerzner, B. F. Gage, K. E. Freedland, and M. W. Rich, “Predictors of mortality in younger and older patients with heart failure and preserved or reduced left ventricular ejection fraction,” American Heart Journal, vol. 146, no. 2, pp. 286–290, 2003.

[35] J. P. Ferreira, W. Ouwerkerk, B. T. Santema et al., “Differences in biomarkers and molecular pathways according to age for patients with HFrEF,” Cardiovascular Research, vol. 117, no. 10, pp. 2228–2236, 2021.
[38] G. Sayer and G. Bhat, “The renin-angiotensin-aldosterone system and heart failure,” *Cardiology Clinics*, vol. 32, no. 1, pp. 21–32, 2014.

[39] M. R. Bristow, D. P. Kao, K. K. Breathett et al., “Structural and functional phenotyping of the failing heart: is the left ventricular ejection fraction obsolete?,” *JACC: Heart Failure*, vol. 5, no. 11, pp. 772–781, 2017.

[40] J. Lupón, C. Diez-López, M. de Antonio et al., “Recovered heart failure with reduced ejection fraction and outcomes: a prospective study,” *European Journal of Heart Failure*, vol. 19, no. 12, pp. 1615–1623, 2017.

[41] P. C. Chang, S. F. Lin, Y. Chu et al., “LCZ696 therapy reduces ventricular tachyarrhythmia Inducibility in a myocardial infarction-induced heart failure rat model,” *Cardiovascular Therapeutics*, vol. 2019, Article ID 6032631, 9 pages, 2019.

[42] Y. Sun, S. Song, Y. Zhang et al., “Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure,” *ESC Heart Failure*, vol. 9, no. 1, pp. 667–675, 2022.

[43] S. Pathadka, V. K. C. Yan, X. Li et al., “Hospitalization and mortality in patients with heart failure treated with sacubitril/valsartan vs. Enalapril: a real-world, population-based study,” *Frontiers in Cardiovascular Medicine*, vol. 7, article 602363, 2021.

[44] T. A. McDonagh, M. Metra, M. Adamo et al., “2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure,” *European Heart Journal*, vol. 42, no. 36, pp. 3599–3726, 2021.